Lexeo Therapeutics on its $100 Million IPO
Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering. Partners Eric Blanchard, Peter Byrne and Div Gupta led the Cooley team advising Lexeo.
Abivax on its $235.8 Million IPO
Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering. Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.
Instacart on its $660 Million IPO
Cooley represented Instacart, the leading grocery technology company in North America, on its $660 million initial public offering. Partners Jon Avina, Rachel Proffitt, Jonie Kondracki and Milson Yu led the Cooley team advising Instacart.
RayzeBio on its $357.6 Million IPO
Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering. Partners Carlos Ramirez, Charlie Kim and Marya Postner led the Cooley team advising RayzeBio.
Neumora Therapeutics on its $250.1 Million IPO
Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital […]
ImmuneOnco Biopharmaceuticals on its HK$319 Million IPO
Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million global initial public offering and listing on the Hong Kong Stock Exchange under stock code 1541. Partners Yiming Liu and Michael Yu led the Cooley team.
Laekna on its HK$791 Million IPO
Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date. Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company. Partners […]
Turnstone Biologics on its $80 Million IPO
Cooley advised Turnstone Biologics, a clinical-stage biotechnology company, on its upsized $80 million initial public offering. Lawyers Div Gupta, Ryan Sansom, Lila Hope, Alexa Smith and Valerie Sapozhnikova led the Cooley team advising Turnstone.
Apogee Therapeutics on its $345.1 Million IPO
Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company. Jefferies, TD Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering. Partners Div Gupta, Charlie Kim and Kristin VanderPas […]
Sagimet Biosciences on its $85 Million IPO
Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million. Goldman Sachs & Co., Cowen and Company and Piper Sandler & Co. acted as joint book-running managers for the offering, while JMP Securities acted as lead manager. Partners John McKenna, […]